JP7783631B2 - ベクターとしてのアレナウイルス - Google Patents

ベクターとしてのアレナウイルス

Info

Publication number
JP7783631B2
JP7783631B2 JP2022526205A JP2022526205A JP7783631B2 JP 7783631 B2 JP7783631 B2 JP 7783631B2 JP 2022526205 A JP2022526205 A JP 2022526205A JP 2022526205 A JP2022526205 A JP 2022526205A JP 7783631 B2 JP7783631 B2 JP 7783631B2
Authority
JP
Japan
Prior art keywords
seq
arenavirus
virus
certain embodiments
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022526205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500928A (ja
JP2023500928A5 (https=
Inventor
ピンスチェワー ダニエル
ボニーラ ピンスチェワー ウェルディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Publication of JP2023500928A publication Critical patent/JP2023500928A/ja
Publication of JP2023500928A5 publication Critical patent/JP2023500928A5/ja
Application granted granted Critical
Publication of JP7783631B2 publication Critical patent/JP7783631B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022526205A 2019-11-07 2020-11-06 ベクターとしてのアレナウイルス Active JP7783631B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932214P 2019-11-07 2019-11-07
US62/932,214 2019-11-07
PCT/EP2020/081393 WO2021089853A1 (en) 2019-11-07 2020-11-06 Arenaviruses as vectors

Publications (3)

Publication Number Publication Date
JP2023500928A JP2023500928A (ja) 2023-01-11
JP2023500928A5 JP2023500928A5 (https=) 2023-11-14
JP7783631B2 true JP7783631B2 (ja) 2025-12-10

Family

ID=73198316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526205A Active JP7783631B2 (ja) 2019-11-07 2020-11-06 ベクターとしてのアレナウイルス

Country Status (7)

Country Link
US (1) US20220380805A1 (https=)
EP (1) EP4055173A1 (https=)
JP (1) JP7783631B2 (https=)
CN (1) CN114981443A (https=)
AU (1) AU2020377504A1 (https=)
CA (1) CA3160032A1 (https=)
WO (1) WO2021089853A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2604695T1 (sl) 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
JP6818551B2 (ja) 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
AU2016274655B2 (en) 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
DK3373959T3 (da) 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
US20240229073A1 (en) 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
WO2022269362A2 (en) * 2021-06-21 2022-12-29 Vaxxinova International B.V. Veterinary viral vector
CA3236106A1 (en) 2021-11-08 2023-05-11 Henning Lauterbach Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507536A (ja) 2007-12-27 2011-03-10 ユニヴァーシテト チューリッヒ 複製欠損アレナウイルスベクター
JP2017503482A (ja) 2013-12-03 2017-02-02 ホオキパ バイオテック エージー Ｃｍｖワクチン
JP2017535267A (ja) 2014-11-13 2017-11-30 ウニヴァシテ デ ジュネーブＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｇｅｎｅｖｅ ワクチンベクターとしての３分節型アレナウイルス
JP2018518172A (ja) 2015-06-10 2018-07-12 ホオキパ バイオテック エージー Ｈｐｖワクチン
JP2018536433A (ja) 2015-11-04 2018-12-13 ホオキパ バイオテック エージー Ｂ型肝炎ウイルスに対するワクチン

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE102004034461B4 (de) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
DK3373959T3 (da) * 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
IL262963B2 (en) 2016-05-18 2025-01-01 Hookipa Biotech Gmbh Trisegmented PICHINDE viruses as vaccine vectors
US20240229073A1 (en) * 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507536A (ja) 2007-12-27 2011-03-10 ユニヴァーシテト チューリッヒ 複製欠損アレナウイルスベクター
JP2017503482A (ja) 2013-12-03 2017-02-02 ホオキパ バイオテック エージー Ｃｍｖワクチン
JP2017535267A (ja) 2014-11-13 2017-11-30 ウニヴァシテ デ ジュネーブＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｇｅｎｅｖｅ ワクチンベクターとしての３分節型アレナウイルス
JP2018518172A (ja) 2015-06-10 2018-07-12 ホオキパ バイオテック エージー Ｈｐｖワクチン
JP2018536433A (ja) 2015-11-04 2018-12-13 ホオキパ バイオテック エージー Ｂ型肝炎ウイルスに対するワクチン

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATURE COMMUNICATIONS，2017年，Vol.8, No.15327，pp.1-13
Virology Journal，2018年，Vol.15, No.99，pp.1-7

Also Published As

Publication number Publication date
CA3160032A1 (en) 2021-05-14
EP4055173A1 (en) 2022-09-14
JP2023500928A (ja) 2023-01-11
CN114981443A (zh) 2022-08-30
WO2021089853A1 (en) 2021-05-14
AU2020377504A1 (en) 2022-06-02
US20220380805A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
JP7783631B2 (ja) ベクターとしてのアレナウイルス
JP7547433B2 (ja) ワクチンベクターとしての三セグメントピチンデウイルス
JP7796680B2 (ja) ワクチンベクターとしての３分節型アレナウイルス
US20240229073A1 (en) Arenaviruses as vectors
HK40036451B (en) Tri-segmented arenaviruses as vaccine vectors
HK40036451A (en) Tri-segmented arenaviruses as vaccine vectors
HK1244034B (en) Tri-segmented arenaviruses as vaccine vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241209

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20250304

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251120

R150 Certificate of patent or registration of utility model

Ref document number: 7783631

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150